# Validation Summary Report

**System**: Clinical Trial Data Pipeline - RECIST 1.1 Module  
**Report Date**: ________________  
**Prepared By**: ________________  
**Reviewed By**: ________________  
**Approved By**: ________________

---

## Executive Summary

This Validation Summary Report documents the validation activities performed for the RECIST 1.1 clinical data derivation pipeline to ensure compliance with FDA 21 CFR Part 11, EU Annex 11, and ICH E6(R2) GCP requirements.

**Validation Status**: ☐ COMPLETE ☐ IN PROGRESS ☐ PENDING

**Overall Assessment**: ☐ SYSTEM VALIDATED ☐ VALIDATION FAILED ☐ REQUIRES ADDITIONAL TESTING

---

## System Description

### Purpose
The RECIST 1.1 Derivation Pipeline processes oncology response data from CDISC SDTM format to ADaM analysis datasets, calculating Best Overall Response (BOR) and time-to-event endpoints (PFS, DoR, OS) according to RECIST 1.1 criteria (Eisenhauer et al. 2009).

### Classification
- **GAMP 5 Category**: Category 4 (Configured Products)
- **Risk Level**: Medium (impacts clinical study analysis, not direct patient care)
- **Regulatory Framework**: FDA 21 CFR Part 11, EU Annex 11, ICH E6(R2)

### Scope of Validation
- R statistical environment (v4.2.0+)
- SAS software (v9.4 M6+)
- RECIST 1.1 derivation macros (4 core programs)
- Time-to-event derivation modules
- QC comparison framework (R diffdf + SAS PROC COMPARE)
- Test data (25 comprehensive subjects)

---

## Validation Activities Summary

### Installation Qualification (IQ)

**Protocol**: `validation/iq_protocol.md`  
**Test Cases**: 6  
**Status**: ☐ Complete ☐ In Progress

| Test ID | Description | Status | Date | Tester |
|---------|-------------|--------|------|--------|
| IQ-001 | R Version Verification | ☐ Pass ☐ Fail | ______ | ______ |
| IQ-002 | R Package Installation | ☐ Pass ☐ Fail | ______ | ______ |
| IQ-003 | SAS Installation | ☐ Pass ☐ Fail | ______ | ______ |
| IQ-004 | File Structure Integrity | ☐ Pass ☐ Fail | ______ | ______ |
| IQ-005 | SAS Autocall Configuration | ☐ Pass ☐ Fail | ______ | ______ |
| IQ-006 | Git Version Control | ☐ Pass ☐ Fail | ______ | ______ |

**IQ Pass Rate**: _____ / 6 (_____%)

**IQ Deviations**: [None / List deviations]

**Evidence Location**: `validation/evidence/iq_*.txt`

---

### Operational Qualification (OQ)

**Protocol**: `validation/oq_protocol.md`  
**Test Cases**: 10  
**Status**: ☐ Complete ☐ In Progress

| Test ID | Description | Priority | Status | Date | Tester |
|---------|-------------|----------|--------|------|--------|
| OQ-RECIST-001 | PR at -30% threshold | Critical | ☐ P ☐ F | ______ | ______ |
| OQ-RECIST-002 | SD at -29.9% | High | ☐ P ☐ F | ______ | ______ |
| OQ-RECIST-003 | PD dual criteria | Critical | ☐ P ☐ F | ______ | ______ |
| OQ-RECIST-004 | CR requires SLD=0 | Critical | ☐ P ☐ F | ______ | ______ |
| OQ-RECIST-005 | Nadir tracking | High | ☐ P ☐ F | ______ | ______ |
| OQ-CONF-001 | 28-day minimum | Critical | ☐ P ☐ F | ______ | ______ |
| OQ-CONF-002 | 84-day maximum | Critical | ☐ P ☐ F | ______ | ______ |
| OQ-CONF-003 | SD 42-day duration | High | ☐ P ☐ F | ______ | ______ |
| OQ-TABLE4-001 | Table 4 integration | Critical | ☐ P ☐ F | ______ | ______ |
| OQ-NEWLES-001 | New lesion = PD | Critical | ☐ P ☐ F | ______ | ______ |

**OQ Pass Rate**: _____ / 10 (_____%)

**Critical Tests Passed**: _____ / 7 (must be 100%)

**OQ Deviations**: [None / List deviations]

**Evidence Location**: `tests/testthat/` test results, `validation/evidence/oq_*.log`

---

### Performance Qualification (PQ)

**Protocol**: `validation/pq_protocol.md`  
**Test Cases**: 5  
**Status**: ☐ Complete ☐ In Progress

| Test ID | Description | Status | Date | Tester |
|---------|-------------|--------|------|--------|
| PQ-001 | Comprehensive dataset (25 subjects) | ☐ Pass ☐ Fail | ______ | ______ |
| PQ-002 | Reproducibility (3 runs) | ☐ Pass ☐ Fail | ______ | ______ |
| PQ-003 | Performance benchmarking | ☐ Pass ☐ Fail | ______ | ______ |
| PQ-004 | Data quality handling | ☐ Pass ☐ Fail | ______ | ______ |
| PQ-005 | Cross-platform validation | ☐ Pass ☐ Fail | ______ | ______ |

**PQ Pass Rate**: _____ / 5 (_____%)

**BOR Concordance**: _____ / 25 subjects (_____%)

**PQ Deviations**: [None / List deviations]

**Evidence Location**: `validation/evidence/pq_*.log`, `outputs/qc_reports/*.html`

---

## Requirements Traceability

**Traceability Matrix**: `validation/requirements_traceability_matrix.csv`

**Total Requirements**: 15  
**Requirements Validated**: _____  
**Traceability Coverage**: _____%

**Requirements Status**:
- Critical requirements validated: _____ / _____ (must be 100%)
- High priority validated: _____ / _____
- Medium priority validated: _____ / _____

---

## Quality Control (QC) Results

### R-Based QC (diffdf)

**Program**: `qc/r/automated_comparison.R`

**Datasets Compared**:
- ADSL: ☐ Pass ☐ Fail - Discrepancies: _____
- ADRS: ☐ Pass ☐ Fail - Discrepancies: _____
- ADTTE: ☐ Pass ☐ Fail - Discrepancies: _____

**QC Reports**: `outputs/qc_reports/r_comparison_*.html`

### SAS-Based QC (PROC COMPARE)

**Programs**: `qc/sas/compare_*.sas`

**Datasets Compared**:
- ADSL: ☐ Pass ☐ Fail - Discrepancies: _____
- ADRS: ☐ Pass ☐ Fail - Discrepancies: _____
- ADTTE: ☐ Pass ☐ Fail - Discrepancies: _____

**QC Reports**: `outputs/qc_reports/adsl_compare_*.html`, `adrs_compare_*.html`, `adtte_compare_*.html`

**Overall QC Status**: ☐ PASS ☐ FAIL

---

## CDISC Compliance (Pinnacle 21)

**Validation Report**: `validation/pinnacle21/reports/p21_validation_*.html`

**Validation Date**: ________________  
**P21 Version**: ________________  
**CDISC CT Version**: ________________

**Results**:
- Critical Errors (Red): _____
- Warnings (Yellow): _____
- Notices (Blue): _____

**Status**: ☐ PASS (0 critical errors) ☐ FAIL

**Acceptance Criteria Met**: ☐ Yes ☐ No

---

## Issues and Deviations

**Issue Resolution Log**: `validation/evidence/issue_resolution_log.csv`

**Total Issues Identified**: _____  
**Critical Issues**: _____ (all must be resolved)  
**Major Issues**: _____  
**Minor Issues**: _____

**Issues Resolved**: _____  
**Issues Open**: _____ (must be 0 for validation approval)

**Summary of Critical Issues**:
[List any critical issues and their resolutions]

---

## Test Coverage Analysis

**Code Coverage Report**: `validation/test_coverage_report.html` (generated by covr package)

**Overall Test Coverage**: _____%

**Coverage by Module**:
- RECIST core functions: _____%
- Time-to-event functions: _____%
- QC comparison functions: _____%

**Acceptance Criteria**: ≥80% coverage for critical modules

---

## Validation Conclusion

### Overall Assessment

**System Fitness for Purpose**: ☐ Validated ☐ Not Validated

**Regulatory Compliance**:
- ☐ FDA 21 CFR Part 11 compliant
- ☐ EU Annex 11 compliant
- ☐ ICH E6(R2) GCP compliant
- ☐ GAMP 5 risk-based validation complete

**Recommendation**: ☐ Approve for use in regulatory submissions ☐ Requires additional work

### Known Limitations

1. [List any known limitations]
2. [e.g., "System tested with synthetic data only, not production patient data"]
3. [e.g., "Cross-platform validation limited to 2 of 3 target platforms"]

### User Training Requirements

- [ ] Understanding of RECIST 1.1 criteria
- [ ] SAS programming proficiency
- [ ] R programming proficiency
- [ ] CDISC SDTM/ADaM standards knowledge
- [ ] QC procedures and validation concepts

---

## Signature and Approval

### Validation Lead

I certify that the validation activities documented in this report have been executed according to the approved validation protocols and that the results demonstrate the system is fit for its intended purpose.

**Name**: ________________________________  
**Title**: ________________________________  
**Signature**: ________________________________  
**Date**: ________________________________

### Quality Assurance Manager

I certify that the validation activities meet regulatory requirements (FDA 21 CFR Part 11, EU Annex 11, ICH E6(R2)) and organizational quality standards.

**Name**: ________________________________  
**Title**: ________________________________  
**Signature**: ________________________________  
**Date**: ________________________________

### Study Director / Sponsor Representative

I approve the use of this validated system for clinical data analysis and regulatory submissions.

**Name**: ________________________________  
**Title**: ________________________________  
**Signature**: ________________________________  
**Date**: ________________________________

### Regulatory Affairs (if required)

I certify that this validation package is suitable for inclusion in regulatory submissions to FDA/EMA.

**Name**: ________________________________  
**Title**: ________________________________  
**Signature**: ________________________________  
**Date**: ________________________________

---

## Appendices

### Appendix A: Referenced Documents
- IQ Protocol: `validation/iq_protocol.md`
- OQ Protocol: `validation/oq_protocol.md`
- PQ Protocol: `validation/pq_protocol.md`
- Requirements Traceability Matrix: `validation/requirements_traceability_matrix.csv`
- Validation README: `validation/README.md`

### Appendix B: Evidence Files
- All test execution evidence: `validation/evidence/`
- QC comparison reports: `outputs/qc_reports/`
- Pinnacle 21 validation: `validation/pinnacle21/reports/`
- Test coverage report: `validation/test_coverage_report.html`

### Appendix C: References
1. FDA 21 CFR Part 11: Electronic Records; Electronic Signatures (1997)
2. EU Annex 11: Computerised Systems (2011)
3. ICH E6(R2): Good Clinical Practice (2016)
4. GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (2008)
5. Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
6. CDISC ADaM Implementation Guide v1.1 (2016)
7. FDA Guidance: Process Validation - General Principles and Practices (2011)

---

**End of Validation Summary Report**
